Targeting Neoantigens with Invariant Natural Killer T Cells
Time: 1:00 pm
day: Day Two
Details:
- MiNK therapeutics is developing iNKT-based allogeneic cell therapy products for cancer. Invariant Natural Killer T cells (iNKT) recognize glycolipids presented on CD1d through their invariant TCR.
- iNKT cells can be engineered to stably express a 2nd TCR, and both TCRs are fully functional
- We are developing a portfolio of phospho-peptide neoantigen-specific TCRs for iNKT-based applications
